Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Healy

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 23, 2010
Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic painJames W Myatt, Mark P Healy, Gianpaolo S Bravi, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2007
Identification of novel glycine sulfonamide antagonists for the EP1 receptorStephen C McKeown, Adrian Hall, Richard Blunt, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonistsAdrian Hall, Stephen Atkinson, Susan H Brown, et al.
Bioorganic & Medicinal Chemistry Letters|April 12, 2018
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP<sub>4</sub> receptor partial agonist for the treatment of painMark P Healy, Amanda C Allan, Kristin Bailey, et al.
The Journal of Clinical Psychiatry|August 6, 2025
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept StudyRichard C Shelton, Robert E Litman, Howard Hassman, et al.
Prostate Cancer and Prostatic Diseases|January 13, 2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomyA J Armstrong, S Halabi, P Healy, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2011
Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonistMairi Sime, Amanda C Allan, Paul Chapman, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Diabetes|January 29, 2015
Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesityOrla M Finucane, Claire L Lyons, Aoife M Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinaseJames E Tarver, Theodore C Jessop, Marianne Carlsen, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Bioorganic & Medicinal Chemistry Letters|June 23, 2010
Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic painJames W Myatt, Mark P Healy, Gianpaolo S Bravi, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2007
Identification of novel glycine sulfonamide antagonists for the EP1 receptorStephen C McKeown, Adrian Hall, Richard Blunt, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonistsAdrian Hall, Stephen Atkinson, Susan H Brown, et al.
Bioorganic & Medicinal Chemistry Letters|April 12, 2018
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP<sub>4</sub> receptor partial agonist for the treatment of painMark P Healy, Amanda C Allan, Kristin Bailey, et al.
The Journal of Clinical Psychiatry|August 6, 2025
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept StudyRichard C Shelton, Robert E Litman, Howard Hassman, et al.
Prostate Cancer and Prostatic Diseases|January 13, 2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomyA J Armstrong, S Halabi, P Healy, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2011
Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonistMairi Sime, Amanda C Allan, Paul Chapman, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Diabetes|January 29, 2015
Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesityOrla M Finucane, Claire L Lyons, Aoife M Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinaseJames E Tarver, Theodore C Jessop, Marianne Carlsen, et al.
Pageof 22